scholarly journals Stem Cell Therapy in Treating Type 1 Diabetes Mellitus –Potential and Ethical Issues.

2021 ◽  
Author(s):  
Nursuaidah Abdullah ◽  
Marjanu Hikmah Elias
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Cell Transplant ◽  
Exogenous Insulin ◽  
Hematopoietic Stem ◽  
Wide Range

Type 1 diabetes (T1D) is a deficiency in insulin production which is mainly due to loss of ?-cell pancreatic islets. Patients with T1D need to be given exogenous insulin regularly. While improvements in the delivery of insulin and glucose monitoring methods have been effective in improving patient safety, insulin therapy is not a cure and is often associated with complications and debilitating hypoglycaemic episodes. Meanwhile, pancreas or islet transplantation as a gold standard only promises temporary freedom from exogenous insulin and suffers from issues of its own. Stem cell therapy may provide a more permanent solution, given stem cells’ immunomodulatory characteristics and ability to self-renew and distinguish into specific cells. In this sense, the therapeutic potentials of stem cells are addressed in this study. These stem cells cover a wide range of treatments for T1D including embryonic stem cells, induced pluripotent stem cells, bone-marrow derived hematopoietic stem cells and multipotent mesenchymal stromal cells. The challenges faced by the current stem cell transplant in T1D treatment and Islamic viewpoints regarding ethics in stem cell research and therapy are also discussed. In conclusion, stem cell therapy offers a safe and efficient alternative treatment for T1D. However, besides the fatwa from Fatwa Committee of Selangor, the lack of Malaysian stem cells ethics should be further addressed.

Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes

2009 ◽  
Vol 35 (2) ◽  
pp. 85-93 ◽  
Author(s):  
L. Vija ◽  
D. Farge ◽  
J.-F. Gautier ◽  
P. Vexiau ◽  
C. Dumitrache ◽  
...  
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals MECHANISMS IN ENDOCRINOLOGY: Towards the clinical translation of stem cell therapy for type 1 diabetes

2017 ◽  
Vol 177 (4) ◽  
pp. R159-R168 ◽  
Author(s):  
Daniel Espes ◽  
Joey Lau ◽  
Per-Ola Carlsson
Keyword(s):  
Stem Cells ◽  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Clinical Translation ◽  
Special Focus ◽  
Insulin Producing Cells ◽  
Potential Risks

Insulin-producing cells derived from human embryonic stem cells (hESCs) or induced pluripotent stem cells (iPSCs) have for long been a promising, but elusive treatment far from clinical translation into type 1 diabetes therapy. However, the field is now on the verge of moving such insulin-producing cells into clinical trials. Although stem cell therapies provide great opportunities, there are also potential risks such as teratoma formation associated with the treatment. Many considerations are needed on how to proceed with clinical translation, including whether to use hESCs or iPSCs, and whether encapsulation of tissue will be needed. This review aims to give an overview of the current knowledge of stem cell therapy outcomes in animal models of type 1 diabetes and a proposed road map towards the clinical setting with special focus on the potential risks and hurdles which needs to be considered. From a clinical point of view, transplantation of insulin-producing cells derived from stem cells must be performed without immune suppression in order to be an attractive treatment option. Although costly and highly labour intensive, patient-derived iPSCs would be the only solution, if not clinically successful encapsulation or tolerance induction protocols are introduced.

scholarly journals The Feasibility and Applicability of Stem Cell Therapy for the Cure of Type 1 Diabetes

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1589
Author(s):  
Ryota Inoue ◽  
Kuniyuki Nishiyama ◽  
Jinghe Li ◽  
Daisuke Miyashita ◽  
Masato Ono ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Islet Cells ◽  
Autologous Transplantation ◽  
Insulin Injection ◽  
Islet Cell Transplantation ◽  
The Impact

Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.

scholarly journals Intestinal myofibroblasts: targets for stem cell therapy

2011 ◽  
Vol 300 (5) ◽  
pp. G684-G696 ◽  
Author(s):  
R. C. Mifflin ◽  
I. V. Pinchuk ◽  
J. I. Saada ◽  
D. W. Powell
Keyword(s):  
Stem Cells ◽  
Smooth Muscle ◽  
Stem Cell ◽  
Cell Therapy ◽  
Lamina Propria ◽  
Stem Cell Therapy ◽  
Intestinal Inflammation ◽  
Mesenchymal Cells ◽  
Hematopoietic Stem ◽  
Intestinal Lamina Propria

The subepithelial intestinal myofibroblast is an important cell orchestrating many diverse functions in the intestine and is involved in growth and repair, tumorigenesis, inflammation, and fibrosis. The myofibroblast is but one of several α-smooth muscle actin-positive (α-SMA+) mesenchymal cells present within the intestinal lamina propria, including vascular pericytes, bone marrow-derived stem cells (mesenchymal stem cells or hematopoietic stem cells), muscularis mucosae, and the lymphatic pericytes (colon) and organized smooth muscle (small intestine) associated with the lymphatic lacteals. These other mesenchymal cells perform many of the functions previously attributed to subepithelial myofibroblasts. This review discusses the definition of a myofibroblast and reconsiders whether the α-SMA+ subepithelial cells in the intestine are myofibroblasts or other types of mesenchymal cells, i.e., pericytes. Current information about specific, or not so specific, molecular markers of lamina propria mesenchymal cells is reviewed, as well as the origins of intestinal myofibroblasts and pericytes in the intestinal lamina propria and their replenishment after injury. Current concepts and research on stem cell therapy for intestinal inflammation are summarized. Information about the stem cell origin of intestinal stromal cells may inform future stem cell therapies to treat human inflammatory bowel disease (IBD).

scholarly journals Targeting Programmed Cell Death to Improve Stem Cell Therapy: Implications for Treating Diabetes and Diabetes-Related Diseases

2021 ◽  
Vol 9 ◽  
Author(s):  
Qi Zhang ◽  
Xin-xing Wan ◽  
Xi-min Hu ◽  
Wen-juan Zhao ◽  
Xiao-xia Ban ◽  
...  
Keyword(s):  
Stem Cells ◽  
Cell Death ◽  
Stem Cell ◽  
Programmed Cell Death ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Therapeutic Effects ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Wide Range

Stem cell therapies have shown promising therapeutic effects in restoring damaged tissue and promoting functional repair in a wide range of human diseases. Generations of insulin-producing cells and pancreatic progenitors from stem cells are potential therapeutic methods for treating diabetes and diabetes-related diseases. However, accumulated evidence has demonstrated that multiple types of programmed cell death (PCD) existed in stem cells post-transplantation and compromise their therapeutic efficiency, including apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis. Understanding the molecular mechanisms in PCD during stem cell transplantation and targeting cell death signaling pathways are vital to successful stem cell therapies. In this review, we highlight the research advances in PCD mechanisms that guide the development of multiple strategies to prevent the loss of stem cells and discuss promising implications for improving stem cell therapy in diabetes and diabetes-related diseases.

Stem cell therapy and research

2002 ◽  
Vol 10 (3) ◽  
pp. 359-367 ◽  
Author(s):  
ROBIN LOVELL-BADGE
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Embryonic Stem Cells ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Stem Cell Research ◽  
Embryonic Stem ◽  
Early Embryos ◽  
Wide Range ◽  
Potential Use

Stem cells are capable of regenerating tissue cells. They have an important potential use in a wide range of therapies, especially as an alternative to organ transplantation, with the advantage that they can be derived from the patient and thus avoid rejection. Embryonic stem cells are potentially capable of forming all kinds of cells. Their use is controversial however, because they are derived from early embryos and because, if they were to match the patient, they would have to be obtained using the same techniques that could, in theory, be used to produce cloned individuals. This article discusses the uses and problems of stem cell research and therapy.

scholarly journals Stem-cell therapy for type 1 diabetes

2007 ◽  
Vol 7 (5) ◽  
pp. 326-326
Author(s):  
Olive Leavy
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy

scholarly journals Stem Cell Therapy to Cure Type 1 Diabetes: From Hype to Hope

2013 ◽  
Vol 2 (5) ◽  
pp. 328-336 ◽  
Author(s):  
Preeti Chhabra ◽  
Kenneth L. Brayman
Keyword(s):  
Type 1 Diabetes ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy
Sign in / Sign up

Export Citation Format

Share Document